Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 23
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Axonex AI Group Ltd
AXNX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.13
0.0302
2.75%
Dern. MÀJ: Oct 23, 5:54 AM
Get Report
Aperçu
Actualités
Prévisions de résultats
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Fractionnement d'actions:
Axonex AI Group Ltd s'est récemment scindé Thursday, October 22, 2026 avec un ratio de 2:5
Axonex AI Group Financials
Axonex AI Group (AXNX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Axonics Q3 Sales $116.20M Beat $113.50M Estimate; EPS $0.00 Vs $0.08 YoY
Axonics (NASDAQ:AXNX) reported quarterly sales of $116.20 million which beat the analyst consensus estimate of $113.50 million by 2.38 percent. This is a 24.81 percent increase over sales of $93.10 million the same
Benzinga Newsdesk
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
Axonics, Inc. (NASDAQ: AXNX) has received regulatory approval from the Therapeutic Goods Administration to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia.
Zacks
PRO
Axonics Q1 EPS $(0.38) Misses $(0.08) Estimate, Sales $91.41M Beat $89.59M Estimate
Axonics (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.08) by 375 percent. This is a 100 percent decrease over losses of $(0.19) per share from the same
Benzinga Newsdesk
Axonics Q4 EPS $0.13 Beats $0.06 Estimate, Sales $109.73M Beat $107.33M Estimate
Axonics (NASDAQ:AXNX) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.06 by 116.67 percent. This is a 1200 percent increase over earnings of $0.01 per share from the same
Happy Mohamed
Why Medical Devices Giant Boston Scientific Shares Are Rising Today
Boston Scientific shares surge in premarket trading following strong Q4 results, beating revenue estimates, amid positive outlook for 2024.
Nabaparna Bhattacharya
Why Is Bladder Disorder Focused Axonics Stock Trading Higher Today?
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $7
Vandana Singh
